Micrus Design Technology

Micrus Endovascular, originally founded as Micrus Design Technology, is a medical device company specializing in the development and commercialization of minimally invasive systems for treating neurovascular diseases. The company's primary focus is on hemorrhagic and ischemic stroke, offering a comprehensive portfolio of products including embolic coils, stents, and delivery systems for treating brain aneurysms. Its innovative technologies, such as the Cerecyte and DeltaPaq coil systems, are designed to promote stable occlusion and healing of vascular defects. Founded in 1996 and headquartered in San Jose, California, the company went public in 2005 before being acquired by Johnson & Johnson in 2010 for approximately $480 million. Its products now form a foundational part of CERENOVUS, the neurovascular division within Johnson & Johnson's MedTech segment.